{"id":"laropiprant-niacin-mk0524a","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Flushing"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Laropiprant is a selective antagonist of the prostaglandin D2 receptor 1 (DP1), which is involved in the regulation of HDL cholesterol levels. Niacin, on the other hand, acts as a receptor agonist to increase HDL cholesterol and reduce triglycerides. The combination of these two mechanisms of action helps to improve lipid profiles and reduce cardiovascular risk.","oneSentence":"Laropiprant/niacin is a combination of a cholesterol absorption inhibitor and a niacin receptor agonist that works to increase HDL cholesterol and reduce triglycerides.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:17.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT01274559","phase":"PHASE3","title":"Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1173},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":"Primary Hypercholesterolemia, Dyslipidemia","enrollment":977},{"nctId":"NCT00533312","phase":"PHASE2","title":"MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hypercholesterolemia","enrollment":407},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":1400},{"nctId":"NCT00111891","phase":"PHASE2","title":"An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":"Dyslipidemia","enrollment":575},{"nctId":"NCT00376584","phase":"PHASE3","title":"Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hypercholesteremia, Hyperlipidemia","enrollment":825},{"nctId":"NCT00378833","phase":"PHASE3","title":"Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":1300},{"nctId":"NCT01583647","phase":"PHASE1","title":"A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06","conditions":"Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus Type 2","enrollment":796},{"nctId":"NCT00384293","phase":"PHASE3","title":"Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hypercholesterolemia, Familial","enrollment":937},{"nctId":"NCT00536510","phase":"PHASE3","title":"Effect of MK0524A on Cholesterol Levels (0524A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":646},{"nctId":"NCT00536237","phase":"PHASE2","title":"MK0524A Phase IIb Study (0524A-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-08","conditions":"Flushing","enrollment":154},{"nctId":"NCT00269204","phase":"PHASE3","title":"Lipid Efficacy/Tolerability Study (0524A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Primary Hypercholesterolaemia, Mixed Hyperlipidaemia","enrollment":1620},{"nctId":"NCT00943124","phase":"PHASE1","title":"MK0524B Bioequivalence Study (0524B-070)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Dyslipidemia","enrollment":220},{"nctId":"NCT00944645","phase":"PHASE1","title":"MK0524A Bioequivalence Study (0524A-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Dyslipidemia","enrollment":188},{"nctId":"NCT01228019","phase":"","title":"Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1166},{"nctId":"NCT00664287","phase":"PHASE3","title":"Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00961636","phase":"PHASE3","title":"A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":1152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK0524A"],"phase":"phase_3","status":"active","brandName":"laropiprant/niacin (MK0524A)","genericName":"laropiprant/niacin (MK0524A)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Laropiprant/niacin is a combination of a cholesterol absorption inhibitor and a niacin receptor agonist that works to increase HDL cholesterol and reduce triglycerides. Used for Hyperlipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}